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Myofibroblastic conversion of mesothelial cells. Overproduction of extracellular matrix (ECM), ac-
Background. The continuous chemical, physical, and in- companied by the presence of activated myofibroblasts
flammatory insults of prolonged continuous ambulatory perito- and local expression of transforming growth factor-
neal dialysis (CAPD) incite mesothelial cell responses, which (TGF-) are the typical manifestations of pathologic fi-
may result in peritoneal fibrosis. The transforming growth fac-
brosis and these have been particularly well demon-tor- (TGF-), especially the isoform TGF-1, has long been
strated in kidney, liver, and lung fibrosis [1]. The spatialknown to play crucial role in the fibrogenic process. Although
and temporal orchestration of myofibroblasts in theseseveral studies have implicated TGF- in peritoneal fibrosis,
the underlying mechanism has not been completely elucidated. pathologic processes implies a dynamic nature of this
Methods. To test the effects of exogenous TGF-1 on meso- type of cells. Quiescent myofibroblasts exist in many
thelial cells, we assessed cytoarchitectural changes of human normal tissues or organs as specific stable cells with the
peritoneal mesothelial cells (HPMC) in in vitro culture by light, potential to be drafted into fibrogenic action. These cells
immunofluorescent, electron and immunoelectron microscopy, include tissue fibroblasts, various types of smooth muscleand differential gene expression analysis using semiquantitative
cells (SMAs), hepatic stellate cells, renal mesangial cells,reverse transcription-polymerase chain reaction (RT-PCR)
intestinal pericryptal cells, pulmonary interstitial con-and cDNA expression array assays.
tractile cells, pericytes of blood vessels and reticular cellsResults. The TGF-1–induced myofibroblastic conversion
was a transdifferentiation process resulting in characteristic in lymph nodes, to cite the principal cell types [2, 3].
myofibroblastic phenotype that included prominent rough en- They reside mainly as stromal cells with or without myoid
doplasmic reticuli (rER) with dilated cisternas, conspicuous features. In contrast to mesenchymal stromal cells, epi-
smooth muscle actin (SMA) myofilaments, frequent intercellu- thelial cells are infrequently converted into myofibro-
lar intermediate and gap junctions, and active deposition of blasts in mature tissues or organs. Recently, we haveextracellular matrix (ECM) and formation of fibronexus. The
observed definite myofibroblast conversion, both func-gene expression array analysis revealed complex modulation
tionally and morphologically, from human differentiatedof gene expression involving cytoskeletal organization, cell ad-
mesothelial cells. These findings are clinically relevanthesion, ECM production, cell proliferation, innate immunity,
cytokine/growth factor signaling, cytoprotection, stress re- because perturbation of mesothelium is unavoidable in
sponse, and many other essential metabolic processes in meso- many major therapeutic procedures such as continuous
thelial cells. ambulatory peritoneal dialysis (CAPD) and abdominal
Conclusion. This report describes myofibroblastic conver- or thoracic surgery. The demonstration that TGF- stim-
sion of mesothelial cells, a previously undefined, yet frequently ulates the mesothelial-myofibroblastic conversion fur-
speculated, cell adaptive or pathogenic process. Our study
ther implies the recruitment of fibrogenic cells from meso-helps to elucidate the complex molecular and cellular events
thelium during serosal inflammation and wound healing.involved in myofibroblastic conversion of mesothelial cells.
We propose that differentiated epithelial cells of mesothelium
convert or transdifferentiate into myofibroblasts, which implies METHODSthe recruitment of fibrogenic cells from mesothelium during
Human peritoneal mesothelial cells culture andserosal inflammation and wound healing.
TGF-1 treatment
We cultured human peritoneal mesothelial cells
(HPMCs) from healthy mesenteric or omental tissues
Key words: myofibroblasts, mesothelial cells, TGF-1, peritoneum. of consenting patients undergoing elective abdominal
surgery. We first selected an intact mesothelial mem-Received for publication April 25, 2002
brane and then firmly clamped it to a base of cylindricaland in revised form August 16, 2002, and October 10, 2002
Accepted for publication November 13, 2002 rings of various diameters (2 to 5 cm) to form isolation
wells. The HPMCs were detached from the serosa by 2003 by the International Society of Nephrology
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trypsin (0.05%, wt/vol) digestion and resuspended in buffer and subsequently treated with 0.1% sodium boro-
hydride and 0.05% Triton X-100. After antibody incuba-growth medium [Dulbecco’s modified Eagle’s medium
(DMEM)/F-12] (Sigma Chemical Co., St. Louis, MO, tion [primary antibody, rabbit anticollagen I, 1:100, No-
vocastra; secondary antibody, ultrasmall gold-conjugatedUSA) supplemented with 10% fetal bovine serum (FBS)
(Gibco BRL, Life Technologies, Grand Island, NY, USA), goat antirabbit immunoglobulin (IgG), F(ab)2, 1:100,
Aurion, The Netherlands], HPMC was further processedantibiotics (100 U/mL penicillin and 100 mg/mL strepto-
mycin) (Gibco), and 2 mmol/L l-glutamine. We used a through postfixation (2.5% glutaraldehyde), silver en-
hancement (R-Gent SE-EM, Aurion, The Netherlands),panel of antibodies to check every batch of initially iso-
lated mesothelial cells to ensure they were positive for and osmication (0.5% OsO4). The HPMC was then dehy-
drated and embedded according to routine procedures.mesothelial markers (cytokeratin, vimentin, calretinin,
and Wilms’ tumor 1 protein [WT-1]), whereas negative The membranes embedded in epoxy resin were sec-
tioned through different directions to facilitate the obser-for endothelial (Ulex Europaeus lectin, type 1 [UEA-1]
and factor VIII), smooth muscle (desmin) and fibroblas- vation of three-dimensional changes of the cells. Thin
sections were viewed and digitally recorded using a trans-tic specific antibody (ASO2) markers (micrographs not
shown). The majority of initial culture exhibited typical mission electron microscope (JEM-1230, JEOL, Japan)
equipped with multiscan CCD camera (791 MSC; Gatan,cobblestone appearance that represented pure mesothe-
lial cells. The propagated cells were harvested and frozen Pleasanton, CA, USA).
for further use. In all experiments, we used HPMC from
Reverse transcription-polymerase chain reaction andthe same pooled stocks of several donors. The confluent
cDNA expression array analysesHPMCs were transferred to lower serum-containing me-
dium (2% FBS) for 48 hours prior to receipt of treatment. For reverse transcription-polymerase chain reaction
(RT-PCR) analysis of HPMC, total RNA was extractedThe HPMCs were continuously exposed to various con-
centrations of recombinant human TGF-1 (0.3 to 25 with RNAzol B (Tel-test, Inc., Friendswood, TX, USA).
Contaminating genomic DNA was removed with RNAase-ng/mL) (R&D Systems, Minneapolis, MN, USA) for 1
week and then transferred to original culture medium free DNAase following the manufacturer’s protocol. First-
strand cDNA was synthesized from total RNA with Su-containing 10% FBS for 1 more week. We have prepared
control groups that were parallel duplication of experi- perscript II RNase H Reverse Transcriptase (Gibco
BRL, Life Technologies) using oligo(dT) as primers.mental groups in terms of cell batch, growth condition,
and culture period. Semiquantitative evaluation of collagen I (COL1A1)
and -smooth muscle actin (ACTA2) mRNA transcripts
Histology and immunohistochemistry by RT-PCR were performed using following primers:
COL1A1 sense 5-GGCGGCCAGGGCTCCGACCC-3,We grew HPMC on either Transwell membranes (Trans-
well-Clear 3452; Costar, Cambridge, MA, USA) for ultra- antisense 5-AATTCCTGGTCTGGGGCACC-3; ACT-
A2 sense 5-GCTCACGGAGGCACCCCTGAA-3,structural and immunoelectron microscopic studies or in
slide flasks (Lab-Tek II; Nalge Nunc, Naperville, IL, antisense 5-CTGATAGGACATTGTTAGCAT-3. Glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) senseUSA) for immunofluorescent studies. The primary anti-
bodies for immunofluorescent staining of HPMC in- 5-CCACCCATGGCAAATTCCATGGCA-3, anti-
sense 5-TCTAGACGGCAGGTCAGGTCCACC-3cluded those to collagen I (rabbit, 1:20, Novocastra, New-
castle-upon-Tyne, UK), collagen III (goat, 1:20, Santa was used as an internal control. Template concentration
was titrated to yield exponentially amplified productsCruz Biotechnology, Santa Cruz, CA, USA), -smooth
muscle actin (-SMA) (mouse, 1:40, Signet, Cheshire, between 17 and 23 cycles (30-second denaturation at
94C; 30-second annealing at 62C; and 30-second exten-UK), pan-cytokeratin (mouse, 1:50, Sigma), cytokeratin
AE1/AE3 (mouse, 1:40, Sigma), desmin (mouse, 1:40, sion at 72C) (thermal cycler; Perkin-Elmer 2400, Nor-
walk, CT, USA).Sigma), WT-1 (rabbit, 1:50, Santa Cruz), calretinin (rab-
bit, 1:20, Zymed, San Francisco, CA, USA), and fibro- For cDNA expression array analysis (Atlas Human
3.6 Array, Clontech, Palo Alto, CA, USA), we exposedblast-specific ASO2 (mouse, 1:20, Dianova, Hamburg,
Denmark). The secondary antibodies were either rhoda- HPMC in two different concentrations of recombinant
human TGF-1 (1.25 and 5 ng/mL) for 1 week. Un-mine or fluorescein-conjugated antibodies (Jackson Im-
munoResearch, West Grove, PA, USA). Nuclear coun- treated HPMC was used as control. The cDNA probes
were prepared from HPMC according the manufactur-terstains were either 4,6-diamidino-2-phenylindole HCl
(1 g/mL) or propidium iodide (0.5 g/mL). We used er’s instruction (Atlas Pure Total RNA Labeling System,
Clontech). Briefly, HPMC was lysed and total RNA wasthe pre-embedding immunogold method to demonstrate
the distribution of type I collagen in HPMC. The HPMCs isolated by two runs of phenol:chloroform extraction.
Total RNA was further processed through isopropanolgrowing on Transwell membranes were initially fixed
in freshly prepared 3% paraformaldehyde in phosphate precipitation, alcohol wash, and DNAse I digestion. Poly
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A mRNA was isolated from total RNA using biotinyl-
ated oligo(dT) mRNA and streptavidin magnetic beads.
cDNA probes were synthesized by Moloney murine leu-
kemia virus (MMLV) reverse transcriptase in the presence
of cDNA synthesis (CDS) primer mix and [-33P]-dATP
(2500 Ci/mmol;) (Amersham, Piscataway, NJ, USA).
Labeled cDNA was purified by column chromatography
(Nucleospin Extraction Kit, Clonetech). The membranes
of cDNA expression arrays were prehybridized with 0.1
mg/mL of sheared salmon testes DNA (Sigma) at 68C
for 30 minutes. cDNA probes were hybridized to the
arrays at 68C overnight. Membranes were washed four
times with 2 	 saline sodium citrate (SSC) containing
1% sodium dodecyl sulfate (SDS) and twice with 0.1 	
SSC (containing 0.5% SDS) for 30 minutes at 68C. Ac-
quisitions of images were processed by a PhosphorImager
(Molecular Dynamics, Amersham). The data were ana-
lyzed using a specific software for membrane arrays
(AtlasImage 1.5, Clontech). Paired arrays were normal-
ized by averaging the corresponding expression of three
housekeeping genes (ubiquitin, GAPDH, and cytoplasmic
b-actin). We define significant differential expression of
a given gene by greater than 2.0-fold and 25 intensity
value (the minimal differential expression level).
RESULTS
TGF-1 induced morphologic and functional
reformation in differentiated human mesothelial cells
To determine the direct response of mesothelial cells
to TGF-1, we incubated isolated HPMC in TGF-1–
containing medium (0.3 to 25 ng/mL). The mesothelial
cells started to take on the myofibroblastic phenotype
after 72 hours of treatment (Figs. 1 and 2). The minimal
dose of TGF-1 to induce the full spectrum of changes
was 0.6 ng/mL. Morphologic features of these converted
cells met the stringent definition of the myofibroblast, and
these criteria include (1) conspicuous bundles of actin mi-
cro (myo) filaments with interspersed dense bodies running
parallel to the long axis of cells, (2) active deposition of
ECM, (3) well-developed cell-ECM assembly (fibronexus),
(4) frequent intercellular intermediate and gap junctions,
and (5) prominent rough endoplasmic reticuli (rER)
with dilated cisternas [4–6] (Fig. 2). We demonstrated
that myofibroblasts were collagen (type I)-secreting cells
(Figs. 2 and 3). Immunoelectron microscopy localized
type I collagen mainly to the pericellular matrix and in
collagen secretion granules (Fig. 2). Immunofluorescent
and semiquantitative RT-PCR studies confirmed that
Fig. 1. Phase-contrast microscopy of myofibroblastic conversion. (a) The type I collagen and -SMA were de novo synthesized
control mesothelial cells without treatment of transforming growth factor-
after TGF-1 stimulation, while type III collagen con-1 (TGF-1) exhibited epithelial cell morphology with characteristic cob-
blestone-like growth pattern. (b) After continuous treatment of TGF-1 tributed little to the ECM synthesis (Fig. 3). The myofibro-
(0.6 ng/mL) for 7 days, the epithelial morphology of mesothelial cells com- blastic conversion was accompanied by the expression of
pletely converted to spindle fibroblast-like morphology with multilayered
the human fibroblast marker ASO2 [7] and by the losscrisscross growth pattern. (c ) The mesothelial cells still maintained their
myofibroblastic phenotypes after withdrawing TGF-1 for 7 days. of the calretinin (a calcium-binding protein constantly
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Fig. 2. Electron microscopy of myofibroblastic
conversion. (a) The control mesothelial cells
without treatment of transforming growth
factor-1 (TGF-1) showed typical epithelial
monolayer growth with scattered surface micro-
villus structures. (b) TGF-1–induced myofi-
broblastic conversion is characterized by spin-
dle multilayered growth, well-developed actin
bundles decorated with dense bodies running
through the cytoplasm (arrows), and abundant
extracellular matrix formation between cell lay-
ers (double arrows). (c) Abundant rough endo-
plasmic reticuli (rER) is well demonstrated in
this horizontal section of a myofibroblast. (d)
Horizontal section of myofibroblasts demon-
strated numerous convergence of cytoplasmic
myofilaments and extracellular matrix (ECM)
fibrils forming a fibronexus (arrows). The ECM
was mainly composed of randomly oriented col-
lagenous fibrils (double arrows). (e) The junc-
tions between myofibroblasts were principally
intermediate or gap junctions (arrow). ( f ) Im-
munogold stain confirmed the distribution of
type I collagen in pericellular matrix (double
arrows) and secretion granules (arrows) of the
myofibroblasts.
expressed on normal mesothelium) [8] (Fig. 3). The The survey of gene expression associated with
myofibroblastic conversiondown-regulation of calretinin was further proved by
cDNA expression array analysis (Table I, group H). The The further investigation of the expression of 3528
myofibroblasts still expressed prototypical mesothelial genes (Atlas Human 3.6 Array, Clontech Labora-
markers, cytokeratin and vimentin (Fig. 3, photomicro- tories) revealed that 52 genes altered their expression
graph of vimentin not shown). The preservation of cyto- during myofibroblastic conversion, according to our
keratin in all culture cells indicated that there was no definition of significant differential expression (
2.0-fold
contamination of fibroblasts. The myofibroblasts pheno- increase and 25 intensity value) (Table 1). Among these
type persisted at least 1 week after TGF-1 was with- genes, 23 had enhanced expression while 29 showed sup-
pressed expression. For the convenience of discussion,drawn (Figs. 1 and 3).
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Fig. 3. Immunofluorescent and semiquanti-
tative reverse transcription-polymerase chain
reaction (RT-PCR) expression profiles in the
process of myofibroblastic conversion. (a) Im-
munofluorescent expression profiles of type I
collagen, type III collagen, -smooth muscle
actin (-SMA), cytokeratin, calretinin and
ASO2. (b ) Semiquantitative RT-PCR analysis
of mRNA expression of -SMA and type I
collagen. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) served as internal con-
trol. Day 0, the control mesothelial cells with-
out treatment of transforming growth factor-1
(TGF-1); day 7, after continuous treatment
of TGF-1 (0.6 ng/mL); day 14, TGF-1–
treated cells (day 7) maintained another 7 days
in TGF-1–free medium. M, 100 bp DNA lad-
der (MBI Fermentas, arrows 400 bp); 17, 20,
and 23, amplification cycles of PCR.
we categorize these genes into eight groups according morphology or function in a given organ or tissue. For
this reason, it is difficult, if not impossible, to determineto their functional correlation (Table 1, groups A to H).
whether a myofibroblastic differentiation is partial orThe significance and influence of these gene expressions
complete. Despite the inherent heterogeneity of myofi-in myofibroblastic conversion of mesothelial cells are
broblast, the essential phenotypical components in andescribed below.
activated prototypical myofibroblast, for example, myo-
fibroblast in granulation tissue, could serve as a baseline
DISCUSSION of myofibroblastic differentiation. These components,
Myofibroblastic phenotype is dynamically modulated mainly in ultrastructural and immunohistochemical con-
text, would be prominent rER, conspicuous peripheraland is heterogeneous. It might express some specific
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Table 1. Differential gene expression associated with myofibroblastic conversion
Symbol Full name Genbank DELa
Group A
TPM1 Human skeletal muscle -tropomyosin M19715 454
CD44 CD44 antigen (homing function and Indian blood group system) M59040 39
ARHA Ras homolog gene family, member A L25080 32
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha X69550 50
MLCK Myosin light chain kinase U48959 58
VIL2 Villin 2 (ezrin) X51521 107
TMSB4X Thymosin--4, X chromosome M17733 2413
Group B
CDH2 Cadherin 2, type 1, N-cadherin (neuronal) M34064 186
TIMP-1 Tissue inhibitor of metalloproteinase 1 X03124 164
MMP-11 Matrix metalloproteinase 11 (stromelysin 3) X57766 125
SERPINE1 Serine (or cysteine) proteinase inhibitor, clade E X04429 77
(nexin, plasminogen activator inhibitor type 1), member 1
COL4A2 Procollagen IV  2 subunit X05562 49
ITGAV Integrin,  V (vitronectin receptor,  polypeptide, antigen CD51) M14648 32
LOX Lysyl oxidase M94054 25
ITGB8 Integrin, 8 M73780 30
CDH5 Cadherin 5, type 2, VE-cadherin (vascular epithelium) X79981 63
Group C
CCR2 Chemokine (C-C motif) receptor 2 U03882 25
BST1 Bone marrow stromal cell antigen 1 D21878 26
C1S Complement component 1, s subcomponent X06596 49
C3 Complement component 3 K02765 67
BF B factor, properdin X72875 231
Group D
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) U09579 62
PCNA Proliferating cell nuclear antigen M15796 34
PSMC3 Proteasome (prosome, macropain) 26S subunit, ATPase, 3 M34079 35
DAPK-1 Death-associated protein kinase 1 X76104 39
JUN v-jun avian sarcoma virus 17 oncogene homolog J04111 146
Group E
SKIL SKI-like X15219 74
SKI v-ski avian sarcoma viral oncogene homolog X15218 57
EGR-1 Early growth response 1 M62829 51
INHBA Inhibin,  A (activin A, activin AB  polypeptide) J03634 41
BMPR1B Bone morphogenetic protein receptor, type IB U89326 28
Group F
VEGF Vascular endothelial growth factor M32977 359
IL-6 Interleukin 6 (interferon,  2) X04602 161
SCG2 Secretogranin II (chromogranin C) M25756 70
LIF Leukemia inhibitory factor (cholinergic differentiation factor) X13967 52
PDGFRA Platelet-derived growth factor receptor,  polypeptide M21574 38
TNFAIP2 Tumor necrosis factor, -induced protein 2 M92357 30
IL-6ST Interleukin 6 signal transducer (gp 130, oncostatin M receptor) M57230 40
Group G
ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 U07919 43
CYP1B1 Cytochrome P450, subfamily I, polypeptide 1 U03688 61
HSP90A Heat shock 90 kD protein A (Hsp90A; Hsp86; Hspca) X07270 70
HSPA8 Heat shock 70 kD protein 8 Y00371 73
SEPP1 Selenoprotein P, plasma, 1 Z11793 142
Group H
MAN2B1 Lysosomal -mannosidase U60266 42
SNRPE Small nuclear ribonucleoprotein polypeptide E X12466 26
PTPN11 Protein tyrosine phosphatase, nonreceptor type 11 L08807 30
CALB2 Calbindin 2, (29 kD, calretinin) X56667 39
MFI2 Antigen p97 (melanoma associated), melanotransferrin M12154 46
T-STAR Sam68-like phosphotyrosine protein, T-STAR AF069681 55
HNRPU Heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) X65488 57
ADFP Adipose differentiation-related protein X97324 69
NPC2 Niemann-Pick disease, type C2 X67698 74
The genes in each category are ranked according to the differential expression levels (DEL).
a, increased expression; , decreased expression
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myofilaments with focal density, fibronexus junctions, a heren junctions and enhancing adhesion with other
N-cadherin–expressing cells such as smooth muscle cellsprominent Golgi apparatus producing collagen secretion
granules, ECM deposition, gap, and intermediate junc- and fibroblasts. Given thatv integrin combines with 1 of
5 beta integrins (1, 3, 5, 6, or 8) and recognizes thetions, and positive for vimentin and -SMA [2, 4]. Al-
though expansion or reduction of these components in sequence RGD in a variety of ligands [16], the up-regula-
tion of v and down-regulation of 8 implied that cell-an acceptable range to reflect the consequences of func-
tional modulation would not hamper myofibroblastic ECM interactions were of the mesenchymal rather than
epithelial type during myofibroblastic conversion. In ad-designation, it would be favorable to use more stringent
criteria in a given experimental system to avoid misinter- dition to type I collagen, other ECM might be produced.
The increased production of basement membrane mate-pretation of nonspecific cellular adaptive changes. In this
report, we demonstrate the full-spectrum myofibroblas- rial in myofibroblasts was implied by the enhanced ex-
pression of procollagen IV 2 subunit (COL4A2). Thetic conversion of mesothelial cells that exhibits all essen-
tial components of a prototypical myofibroblast. In addi- matrix degradation might be suppressed in myofibro-
blasts, since expression of tissue inhibitor of metallopro-tion, the presence of residual cytokeratin in all our
myofibroblasts directly indicate their origin from meso- teinase (TIMP-1) and serine proteinase inhibitor (PAI-1)
was enhanced. In addition, the expression of metallopro-thelial cells and is an unequivocal evidence against con-
tamination of myofibroblast of other origin. teinases (MMPs) was not enhanced in myofibroblasts
except for expression of MMP-11 (stromelysin 3). TheTo further understand the internal processes of meso-
thelial-myofibroblastic conversion, we compared the dif- main function of activated MMP-11 is not to hydrolyze
major components of ECM but to hydrolyze 1 serineferences of their gene expression. In the present study,
we found altered expression of several genes that regu- PAI [17].
Myofibroblastic conversion also implies alteration oflated, either directly or indirectly, the actin-based cy-
toskeleton (Table 1, group A), and a second set of genes the innate immune system in serosal cavities (Table 1,
group C). Mesothelium is an important barrier againstinvolved in ECM assembly and cell adhesion (Table 1,
group B). The up-regulation of small guanosine triphos- potential pathogenic microorganisms in body cavities.
Both C1s and B-factor (BF) are essential for the activa-phatase (GTPase) Rho, specifically by Rho A (ARHA),
and down-regulation of Rho guanosine diphosphate dis- tion of C3 by generation of C3 convertase through the
classical and alternative pathway respectively. The defi-sociation inhibitor (ARHGDIA) and myosin light chain
kinase (MLCK) might contribute to actin-myosin filament ciency of complement would lead to ineffective clearance
of bacteria on mesothelium [18]. However, the depres-assembly, fibronexus formation, and cell contraction dur-
ing myofibroblastic conversion [9]. One of the ezrin- sion of the complement system, especially C3, might re-
duce bacterial colonization as has been demonstrated onradixin-moesin (ERM) proteins, ezrin (villin 2, VIL2),
and its transmembrane anchorage protein, CD44, were renal tubular epithelium [19], and therefore reduce the
bacterial translocation and reservoir in the peritoneum.altered during myofibroblastic conversion. Both proteins
are essential for Rho-induced cytoskeletal effects, spe- The human mesothelial cells constitutively express bone
marrow stromal cell antigen 1 (BST-1, CD157), a cell-cifically the stress fiber formation [10]. Since ezrin (villin 2)
is also a component of epithelial microvilli, its down-regu- surface glycoprotein that facilitates B lymphopoiesis in
bone marrow [20, 21]. Despite that the functional role oflation might result in loss of mesothelial microvilli dur-
ing myofibroblastic conversion [11]. The thymosin--4 mesothelial BST-1 is not clear, the alternation of BST-1
in peritoneum might significantly affect local extralym-(TMSB4X) is the main intracellular actin–sequestering
peptide and serves as an actin buffer [12]. Down-regula- phoid B-cell differentiation. In addition, low BST-1 might
be necessary to maintain fibroblast morphology sincetion of thymosin--4 (TMSB4X) implied the release of
actin building blocks for myofibroblastic conversion. Like CD157-transfected fibroblasts lost typical elongated spin-
dle morphology [22]. Mesothelial cells also constitutivelykidney mesangial myofibroblasts, mesothelial myofibro-
blasts also expressed abundant sarcomeric thin filament express monocyte chemotactic protein 1 (MCP-1) and its
binding receptor (CCR2). The enhanced CCR2 expres-proteins [skeletal muscle -tropomyosin (TPM1)] [13].
Both cadherins and integrins are also subjected to the sion in myofibroblasts would probably promote hapto-
tactic migration in response to MCP-1 and play an impor-regulation of GTPase Rho A [14, 15]. It is worth noting
that mesothelial cells specifically expressed N-cadherin tant role in myofibroblast recruitment during inflammatory
reactions [23].(CDH2) and VE-cadherin (CDH5). The up-regulation
of N-cadherin and down-regulation of VE-cadherin (Ta- The myofibroblastic conversion might result in quench-
ing cell proliferation through the enhanced expressionble 1, group B) during myofibroblastic conversion im-
plied that myofibroblasts altered homotypic adhesive of cyclin-dependent protein kinase inhibitor, p21cip1, and
the depression of proliferating cell nuclear antigen (PCNA)properties and might therefore promote their migration
and spreading by loosening VE-cadherin–associated ad- (Table 1, group D). p21cip1 can interact with PCNA,
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blocking its activity necessary for DNA replication [24]. tyrosine kinase receptors, VEGFR-1 (Flt-1), VEGFR-2
(KDR). and VEGFR-3 (Flt-4). It thus implied that TGF-JUN, a major component of the activator protein-1
(AP-1) transcriptional complex, was also down-regu- directs myofibroblasts to mediate paracrine signaling of
angiogenesis. This finding has potential clinical signifi-lated during myofibroblastic conversion. The suppres-
sion of JUN might hinder cell cycle progression because cance because recent investigation on VEGF has recog-
nized its pathogenic role in peritoneal microvascular dys-it has been shown that constitutive c-Jun inhibits p21
induction [25]. Recent work indicates that many impor- function and ultrafiltration failure. [32–34] Our finding
is further supported by a recent in vivo study that trans-tant regulators of G1 and S phases are targeted for ubiqui-
tination and subsequent degradation by the 26S protea- duction of TGF-1 gene to peritoneal mesothelial cells
not only enhances VEGF production but also inducessome (PSMC3) [26]. The inhibition of proteasome
(PSMC3) activity would thus reduce cell proliferation. accumulation of -SMA–positive interstitial cells in peri-
toneal membrane. [35] The response of the IL-6 familyOur results implied that TGF-1 is predominantly a cy-
todifferentiating rather than a proliferating growth fac- is similar in that IL-6 and LIF are up-regulated in myofi-
broblasts. Other factors of IL-6 family were not ex-tor. Myofibroblastic conversion did not seem to enhance
apoptosis since the major mediators of programmed cell pressed. The mesothelial cells seemed to be the primary
IL-6 unresponsive cells expressing only IL-6 signal trans-death were unaltered except for the down-regulation of
death-associated protein kinase-1 (DAPK-1), a positive ducer (IL-6ST, gp130) and no gp80. The gp130 was fur-
ther down-regulated after myofibroblast conversion.mediator of apoptosis [27]. Our previous observation
that tumor necrosis factor- (TNF-), but not TGF-, Thus, the IL-6 produced is speculated to mediate para-
crine signaling of other types of cells in the vicinity of ac-activated Fas/Fas-ligand pathway to promote apoptosis
of mesothelial cells also supports this assumption (un- tive myofibroblasts. This functional property of myofi-
broblasts has been frequently described in associationpublished observation).
The modulation of TGF- signaling pathway (Table with tissue repair and the fibrogenic process [36]. The en-
hanced expression of PDGF receptor  polypeptide gene1, group E) during myofibroblast conversion implied
negative feedback regulation with up-regulation of v-ski (PDGFRA) without concomitant expression of PDGFRB
gene implied that -receptor homodimer was the pre-avian sarcoma viral oncogene homolog (SKI) and SKI-
like (SKIL) (SnoN) and concomitant down-regulation dominant PDGF receptor on the myofibroblasts. The
selection of the PDGF signaling system seems to be cell-of the 26S proteasome (PSMC3). It is speculated that
mild-to-moderate feedback up-regulation of these co- type dependent, since liver myofibroblasts showed pre-
dominant up-regulation of PDGF- [37]. Consideringrepressors is mainly for fine-tuning of the selective sup-
pressive effects of TGF- and is functionally distinct that both the A chain and B chain of PDGF are not
expressed in mesothelial cells, the autocrine action offrom their activity in oncogenic transformation, which is
usually promoted by highly expressed SKI/SnoN [28, 29]. PDGF is not expected to participate myofibroblastic con-
version. Since PDGF was reported to be a very potentThe down-regulation of cellular proteasomes might re-
duce the degradation of SnoN and SKI. TGF- enhanced mitogenic factor of myofibroblast, the augmentation of
PDGFR implies that it might serve as a proliferationexpression of the inhibin/activin A subunit (INHBA)
gene and might be responsible only for up-regulation of trigger of mesothelial myofibroblasts [37]. This assump-
tion does not conflict with our observation that TGF-activin A (A-A) in that inhibin  as well as activin
B and C subunits were not expressed during myo- suppresses proliferation of cultured mesothelial cell (un-
published results), since previous study have showed thatfibroblast conversion. Our results also suggested that
several other factors might enhance TGF- signaling TGF- in vitro may inhibit the proliferation of hepatic
myofibroblasts, but promotes their proliferation in vivosystem. These factors included BMPR1B (ALK6), an
alternative type I receptor for TGF- agonists [30], early by a PDGF autocrine loop [38]. The other factor that
might be ascribed to cytokine system is secretogranin IIgrowth response-1 (EGR-1), an early response gene
whose product directly transactivates TGF- in an auto- (SCG2). SCG2 is the precursor of secretoneurin, a potent
chemotactant of fibroblasts, monocytes, endothelial cells,crine fashion [31], and leukemia inhibitory factor (LIF),
a cytokine of the interleukin-6 (IL-6) family that in con- and vascular smooth muscle cells [39].
The pathogenic nature of myofibroblastic conversionjunction with BMP2 acts through STATs, Smads, and
coactivator p300 to activate transcription [31]. was implied by the potential risk of compromising cyto-
protective capability against various cellular stresses orThe expression profiles of cytokine and growth factor
systems implied involvement of vascular endothelial injuries (Table I, group G). One example was the down-
regulation of heat shock 70 kD protein 8 (HSPA8, alsogrowth factor (VEGF), IL-6, and platelet-derived growth
factor (PDGF) in myofibroblast conversion (Table 1, termed Hsc70 or Hsp73) and heat shock 90 kD protein
A (HSP90A) without concomitant elevation of othergroup F). The strong augmentation of VEGF expression
was not accompanied by the expression of its three major inducible heat shock proteins. HSPA8 is not only a con-
Yang et al: Myofibroblast conversion of mesothelial cells1538
stitutively expressed molecular chaperone but also an CONCLUSION
adenosine triphosphatase (ATPase) that releases clath- This study describes myofibroblastic conversion of
rin from coated vesicles [40]. We also observed sup- mesothelial cells, a previously undefined, yet frequently
pression of some other constitutively expressed cyto- speculated, cell adaptive or pathogenic process. Our
protective factors such as selenoprotein P (SEPP1), study helps to elucidate the complex molecular and cellu-
lar events involved in this process. Our findings alsocytochrome P450 (CYP1B1), and aldehyde dehydroge-
suggest revoking the earlier concept of “multipotentialnase (ALDH1A3) in myofibroblasts. These changes did
subserosal cells” as progenitor cells of both epithelialnot seem to be myofibroblast specific since TGF- also
mesothelial cells and myofibroblasts [46]. Our resultsinduced similar suppression in liver cells [41, 42].
indicate that differentiated mesothelial epithelial cellsFinally, we observed alternations of some ubiquitously
can convert or transdifferentiate to myofibroblasts, an-expressed cellular factors following myofibroblastic con-
other differentiated status of mesothelial cells.version (Table I, group H). The down-regulation of Nie-
mann-Pick disease, type C2 gene (NPC2) could cause
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